Skip to main content
68°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aura Biosciences Inc.
Aura Biosciences to Participate in Upcoming Investor Conferences
February 26, 2024
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
December 07, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Participate in Upcoming Investor Conferences
November 08, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
October 31, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
October 02, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
August 09, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Participate in Upcoming Investor Conferences
May 24, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Participate in the JMP Securities Life Sciences Conference
May 12, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
May 11, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
March 15, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Participate in Upcoming Investor Conferences
February 09, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Participate in Upcoming Investor Conferences
November 03, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress
September 07, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress
September 01, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
August 11, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma
June 22, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting
June 17, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting
May 26, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Participate in Upcoming Investor Conferences
May 25, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
May 12, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting
May 03, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference
May 03, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights
March 23, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)
March 21, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22
March 15, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Participate at the 42nd Annual Cowen Virtual Health Care Conference
February 28, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium
February 14, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tickers
AURA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.